Immuneering (IMRX) Preferred Stock Liabilities (2020 - 2021)
Immuneering's (IMRX) quarterly Preferred Stock Liabilities came in at $82.9 million in Q2 2021, up 292.49% year-on-year from $21.1 million in Q2 2020, and up 124.13% quarter-over-quarter from $37.0 million in Q1 2021.
Immuneering (IMRX) Preferred Stock Liabilities (2020 - 2021) Analysis & Trends
Immuneering's Preferred Stock Liabilities history runs 2 years deep, the most recent figure standing at $82.9 million for Q2 2021.
- On a quarterly basis, Preferred Stock Liabilities rose 292.49% year-over-year to $82.9 million in Q2 2021; TTM through Jun 2021 was $82.9 million, a 292.49% increase from a year earlier, with the FY2020 full-year figure at $21.1 million, changed N/A from the prior year.
- Preferred Stock Liabilities grew to $82.9 million in Q2 2021 per IMRX's latest filing, from $37.0 million in the prior quarter.
- Across five years, Preferred Stock Liabilities topped out at $82.9 million in Q2 2021 and bottomed at $21.1 million in Q2 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | - |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | - |
| 10 | Immuneering | 279.33 Mn | 279.33 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2021 | 82.89 Mn |
| Mar 31, 2021 | 36.98 Mn |
| Dec 31, 2020 | 21.12 Mn |
| Sep 30, 2020 | 21.12 Mn |
| Jun 30, 2020 | 21.12 Mn |